<DOC>
	<DOCNO>NCT01860742</DOCNO>
	<brief_summary>The purpose study assess benefit 177Lu-DOTATATE versus interferon α-2b patient progressive , unresectable , non-pancreatic gastrointestinal neuroendocrine tumor resistant therapy somatostatin analogue , term disease control .</brief_summary>
	<brief_title>Randomized Phase III PRRT Versus Interferon</brief_title>
	<detailed_description>This phase III study Peptid Receptor Radionuclide Therapy ( PRRT ) 177Lu-DOTATATE versus Interferon α-2b . Objectives study : 1 . To assess benefit 177Lu-DOTATATE versus interferon α-2b patient progressive , unresectable , non-pancreatic gastrointestinal neuroendocrine tumor , resistant therapy somatostatin analogue , term disease control . 2 . To assess efficacy safety parameter treatment arm predictive value tumor 68Ga-DOTATATE PET/CT 18FDG PET/CT uptake baseline , mid ( +/- 16th week ) end ( +/- 32th week ) treatment arm . In interferon arm : 5000000 Units interferon administer subcutaneously preferentially even three time week ( every day ) disease progression . In 177Lu-octreotate arm : Treatment consist 177Lu-DOTATATE intravenous injection fractionate fixed activity 7,4 GigaBecquerel ( 200mCi ) ( +/- 5 % ) , give every 8 ( +/- 1 ) week simultaneous nephroprotective infusion amino acid solution . ( Before amino acid nephroprotection solution , ondansetron , methylprednisolone metoclopramid , give infusion order prevent nausea vomit ) . Approximately 30 min begin aminoacid solution , 177Lu-octreotate injected via second side-line 15-30 minute . The amino acid infusion continue rate end ( total infusion time : 4-6 hour ) . In total , 4 injection 177Lu-DOTATATE plan . However , respect absorded dose limit critical organ ( kidneys bone marrow ) , 4th 177Lu-DOTATATE injection tailor minimal administer activity 4,6 GigaBecquerel . Treatment efficacy assess patient-basis use RECIST 1.1 Progression Free Survival . The value tumor 68Ga-DOTATATE PET/CT 18FDG PET/CT uptake predict image biomarkers also assess arm .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Adult patient ( ≥ 18 yr ) . 2 . Histologyproven nonpancreatic gastrointestinal NETs . 3 . Disease progression SSAs ( SSAsresistant disease ) . Disease progression must document least one following : Radiological disease progression ( accord RECIST 1.1 ) MRI CT last 12 month . Disease progression somatostatin receptorimaging ( PET/CT SPECT/CT ) last 12 month ( apparition new lesion ( ) increase transaxial plane diameter 30 % image modality ) . 4 . There least one target lesion . A target lesion fulfill follow criterion : Uptake high physiological liver uptake baseline 68GaDOTATATE PET/CT Longest transaxial plane diameter ≥ 20mm measure CT MRI ; Not previously irradiate . 5 . Longacting SSAs must discontinue least 4 week study treatment start date , need , switch shortacting analogue must stop 48h treatment date . 6 . Adequate renal function GFR ≥ 50 mL/min/1.73m2 ( evaluated 51CrEDTA test ) . 7 . Adequate bone marrow function : Hemoglobin ≥ 9 g/dL ; Neutrophil ≥ 1.5·109/L ; Platelet count ≥ 100·109/L . 8 . Adequate liver function : Total Bilirubin ≤ 2xULN ; Transaminases ( AST ALT ) ≤ 5xULN ; Serum albumin &gt; 3.0 g/dL normal prothrombin time ( &gt; 70 % ) unless patient coumarin anticoagulation therapy . 9 . ECOG Performance Status ≤ 1 . 10 . Women childbearing potential men partner childbearing potential must agree use highly effective form contraception duration study participation six month end treatment . A pregnancy test ( serum ) must perform within 2 week prior inclusion every female patient childbearing potential must negative . 11 . Patient 's write informed consent obtain prior study specific procedure . 12 . All necessary baseline procedure perform within 2 week prior randomization date . 1 . Resectable tumor curative intent . 2 . Any major surgery within last 6 week prior inclusion study . 3 . Radiotherapy , chemotherapy , embolization , mammalian target rapamycin ( mTOR ) inhibitor , receptor tyrosinekinase inhibitor investigational therapy within 12 week prior inclusion study . 4 . Previous PRRT MIBG treatment . 5 . Treatment interferon 12 month prior inclusion study . 6 . Presence nonbenign 18FDGpositive lesion ( high 2 x normal liver ( thoracic aorta uptake SUVmax case liver involvement ) ) without significant 68GaDOTATATE uptake . 7 . Uncontrolled congestive heart failure ( NYHA stade ≥ 2 ) . 8 . Diffuse bone marrow infiltration baseline 68GaDOTATATE PET/CT confirm MRI . 9 . Prior external beam radiotherapy kidneys 25 % bone marrow . 10 . Patients know uncontrolled brain metastasis . 11 . History active malignant disease clinical remission le 5 year ( except case non melanoma skin cancer situ cervical carcinoma ) . 12 . Known autoimmune hepatitis . 13 . Patients organ transplantation immunosuppressive therapy . 14 . Patients significant medical , neuropsychiatric , surgical condition , currently uncontrolled treatment , , investigator 's opinion , may interfere completion study . 15 . Hypersensitivity interferon α2b component product . 16 . Pregnant lactating patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Peptide Receptor Radionuclide Therapy ( PRRT )</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Interferon alpha</keyword>
</DOC>